AEON News
Get all your AEON Biopharma news in one place.
AEON Biopharma Completes Enrollment in Phase 2 Clinical Study of ABP-450 in Cervical Dystonia
Topline data expected to be announced in the second half of 2022 Newport Beach, Calif., April 11, 2022 – AEON Biopharma, Inc. (“AEON” or the “Company”), a private clinical-stage biopharmaceutical…
AEON Biopharma Announces the Appointment of Alex Wilson as General Counsel
Newport Beach, Calif., August 11, 2021 – AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for therapeutic…
AEON Biopharma Appoints Dr. Chad K. Oh as Chief Medical Officer to Lead Clinical Development of ABP-450 Across Several Therapeutic Indications
Newport Beach, Calif., June 8, 2021 – AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of therapeutic indications for its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA)…
AEON Biopharma Doses First Patient in Phase 2 Trial of ABP-450 for the Treatment of Cervical Dystonia
-Topline data expected in early-2022- Newport Beach, Calif., April 5, 2021 – AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of therapeutic indications for its proprietary…
A Transformation of the Healthcare Experience
Empowering patients, enabling specialists, and driving innovation in the health and wellness industry.
AEON Biopharma Initiates Enrollment in Phase 2 Trial of ABP-450 for the Preventive Treatment of Migraine
-Clinical trial will enroll both episodic and chronic migraine patients- -Protocol utilizes streamlined treatment paradigm with fewer injections- -Topline data expected in mid-2022- Newport Beach, Calif., March 8, 2021 –…
AEON Biopharma Announces FDA Acceptance of IND for ABP-450 as a Treatment for Cervical Dystonia; Secures $25 Million Investment
-Critical milestone transitions AEON Biopharma to clinical-stage company--Moving directly into Phase 2 clinical trial expected to begin in the first half of 2021--Investment expected to provide funding for clinical programs…
AEON Biopharma Appoints Chris Carr as Chief Financial Officer and Scott Akamine as General Counsel
Biopharma Firm Continues to Build Industry Leading Management Team; Poised for Next Phase of Growth in Therapeutic Toxin Market NEWPORT BEACH, Calif., October 1, 2019 – AEON Biopharma, an emerging…
AEON Biopharma Appoints BOTOX® Therapeutic Head as President and Chief Executive Officer
Dynamic Industry Veteran Led Multi-Billion Dollar Therapeutic Neurotoxin Portfolio NEWPORT BEACH, Calif., May 13, 2019 /PRNewswire/ -- ALPHAEON Corporation announced today that its Board of Directors has named Marc Forth as President and Chief Executive…